Multiple preventive & treatment options are now authorized by the FDA for emergency use in outpatient settings. The Pennsylvania Department of Health (PA DOH) can support LTCFs in accessing these lifesaving products.

### WHAT COVID-19 THERAPEUTICS (Tx) ARE CURRENTLY ALLOCATED BY PA DOH?

<table>
<thead>
<tr>
<th>What are they</th>
<th>Oral antivirals (OAVs)</th>
<th>Monoclonal Antibodies (mAbs) for Treatment</th>
<th>Monoclonal Antibodies for Pre-Exposure Prophylaxis (PrEP)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Oral medications (pills) that prevent multiplication of the COVID-19 virus and help prevent worsening or progression of illness</td>
<td>Intravenous (IV) infusion of antibodies like those produced naturally during COVID-19 infection, preventing worsening or progression of illness</td>
<td>Intramuscular (IM) injection of antibodies that help neutralize the COVID-19 virus to prevent infection and disease in people with compromised immune systems</td>
<td></td>
</tr>
<tr>
<td>Who should get them</td>
<td>Non-hospitalized patients with mild to moderate COVID-19 over 12 years-old (18+ for Lagevrio)</td>
<td>Non-hospitalized patients over 12 years-old when oral antivirals are not available, feasible to use, or clinically appropriate</td>
<td>Immunocompromised patients and those who are not able to be fully vaccinated with any available COVID-19 vaccines due to a history of severe reactions</td>
</tr>
<tr>
<td>When to get them</td>
<td>COVID-positive, within the first 5 days of symptom(s) onset</td>
<td>COVID-positive, within first 7 days of symptom(s) onset</td>
<td>COVID-negative, no known exposure</td>
</tr>
<tr>
<td>Currently EUA authorized Tx</td>
<td>Paxlovid (Pfizer) Lagevrio/ molnupiravir (Merck)</td>
<td>Bebtelovimab (Eli Lilly)</td>
<td>Evusheld (AstraZeneca)</td>
</tr>
<tr>
<td>Efficacy per clinical trials</td>
<td>Reduction in hospitalizations/deaths: Paxlovid 88%; Lagevrio 30%</td>
<td>Reduction of risk in high-risk patients (clinical trial ongoing)</td>
<td>83% reduction in risk of developing COVID-19 symptoms</td>
</tr>
</tbody>
</table>

1. For more information: ASPR [clinical decision aid](https://asprvaluation.spr嚏th.com/) & Tx overview. Consult a healthcare professional to confirm eligibility.

### HOW CAN MY FACILITY ACCESS THESE THERAPEUTICS?

**If you have your own pharmacy on site and/or the ability to prescribe and dispense Tx in your facility...**

- Enroll to be a therapeutics provider with PA DOH
  - Complete PA DOH’s [therapeutics enrollment form](https://health.pa.gov/TherapeuticsProvider/)
  - You will need to be a registered Health Partner Ordering Portal (HPOP) user. If you aren’t already, PA DOH can help create your account upon enrollment. Your facility needs a pharmacy license and/or a licensed medical director to take responsibility
  - See PA DOH’s [COVID-19 therapeutics handbook](https://health.pa.gov/TherapeuticsProvider/) for more information
  - Once you are enrolled, you will receive additional instructions to receive product

**If you use a pharmacy partner that dispenses Tx to you...**

- Check if your pharmacy stocks COVID-19 therapeutics
  - To check if your pharmacy has product(s), use this [locator tool](https://health.pa.gov/TherapeuticsProvider/)
  - or call sites listed on PA DOH’s [website](https://health.pa.gov/TherapeuticsProvider/) to confirm product availability
  - If your pharmacy partner does not have product, [inform them of how they can enroll with PA DOH](https://health.pa.gov/TherapeuticsProvider/); send them the link to the [therapeutics enrollment form](https://health.pa.gov/TherapeuticsProvider/)

**If you have none of the above...**

- Submit a request for oral antivirals from the PA DOH state reserve
  - Skilled Nursing Facilities can request direct shipments of oral antivirals from PA’s reserve; a prescription from a doctor is still required to receive product

### WHERE CAN I FIND ADDITIONAL RESOURCES?

- For more information and the latest updates, please visit: [PA DOH](https://health.pa.gov/), [ASPR](https://asprvaluation.spr嚏th.com/), [CDC](https://www.cdc.gov/), [NIH](https://www.nih.gov/)
- Contact us at [covidtherapeutics@pa.gov](mailto:covidtherapeutics@pa.gov) with any questions

Last updated: 6/2/2022